Receptor activator of nuclear factor kappa b ligand/osteoprotegerin pathway is a promising target to reduce atherosclerotic plaque calcification

Critical Pathways in Cardiology

Volumn 9, Issue 4, 2010, Pages 227-230

  Quercioli, Alessandra ^a,b   Luciano Viviani, Giorgio ^b   Dallegri, Franco ^b   MacH, François ^a,c   Montecucco, Fabrizio ^c  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

atherosclerosis; coronary artery calcium score; coronary artery disease; denosumab; RANKL

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR;

ARTICLE; ATHEROSCLEROTIC PLAQUE; BONE MASS; BONE METASTASIS; CALCIFICATION; CALCIUM HOMEOSTASIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MYELOMA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SIDE EFFECT;

CALCIFICATION, PHYSIOLOGIC; CALCIUM; CELL DIFFERENTIATION; CORONARY ARTERY DISEASE; CORONARY VESSELS; DENDRITIC CELLS; DRUG DISCOVERY; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION MEDIATORS; PLAQUE, ATHEROSCLEROTIC; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RISK FACTORS; TUNICA INTIMA;

EID: 78650322874     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0b013e318200ec27     Document Type: Article

References (33)

1. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337: 1360-1369.
2. Vliegenthart R, Oudkerk M, Hofman A, et al. Coronary calcification im-proves cardiovascular risk prediction in the elderly. Circulation. 2005;112: 572-577.
3. Montecucco F, Steffens S, Mach F. The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clin Dev Immunol. 2007;2007:75805.
4. Virmani R, Burke AP, Farb A, et al. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13-C18.
5. Church TS, Levine BD, McGuire DK, et al. Coronary artery calcium score, risk factors, and incident coronary heart disease events. Atherosclerosis. 2007;190:224-231.
6. Blaha M, Budoff MJ, Shaw LJ, et al. Absence of coronary artery calcification and all-cause mortality. JACC Cardiovasc Imaging. 2009;2: 692-700.
7. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2007;49:378-402.
8. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117:2938-2948.
9. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175-179.
10. Schoppet M, Preissner KT, Hofbauer LC RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb VascBiol. 2002;22:549-553.
11. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292: 490-495.
12. Mosheimer BA, Kaneider NC, Feistritzer C, et al. Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum. 2004;50:2309-2316.
13. Kindle L, Rothe L, Kriss M, et al. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendo-thelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts. JBone Miner Res. 2006;21:193-206.
14. Panizo S, Cardus A, Encinas M, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res. 2009;104:1041-1048.
15. Sandberg WJ, Yndestad A, Oie E, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb VascBiol. 2006;26:857-863.
16. Kiechl S, Schett G, Schwaiger J, et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation. 2007; 116:385-391.
17. Wei T, Wang M, Wang M, et al. Relationship of sRANKL level and vascular calcification score to cardiovascular events in maintenance hemodialysis patients. Blood Purif. 2009;28:342-345.
18. Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcifica-tion without affecting atherosclerosis in LDLR(?/\) mice. Circulation. 2008; 117:411-420.
19. Vik A, Mathiesen EB, Johnsen SH, et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population-the Tromso Study. J Thromb Haemost. 2010;8:898-905.
20. Venuraju SM, Yerramasu A, Corder R, et al. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010;55:2049-2061.
21. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onsetosteoporosis andarterial calcification. GenesDev. 1998;12:1260-1268.
22. Mikami S, Hamano T, Fujii N, et al. Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients. Hypertens Res. 2008;31:1163-1170.
23. Mesquita M, Demulder A, Damry N, et al. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med. 2009; 47:339-346.
24. Quercioli A, Montecucco F, Bertolotto M, et al. Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling. Eur J Clin Invest. 2010;40:645-654.
25. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol. 2009;5:667-676.
26. Anastasilakis AD, Toulis KA, Polyzos SA, et al. RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opin Investig Drugs. 2009;18:1085-1102.
27. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
28. Deodhar A, Dore RK, Mandel D, et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2010;62:569-574.
29. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564-1571.
30. Henry D, von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metas-tases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma [abstract]. Eur J Cancer Suppl. 2009;7:12.Abstract 20LBA.
31. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222-229.
32. Montecucco F, Mach F. Common inflammatory mediators orchestrate patho-physiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford). 2009;48:11-22.
33. Anastasilakis AD, Toulis KA, Goulis DG, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res. 2009;41:721-729.